Abbott Laboratories (NYSE:ABT – Get Free Report) had its target price lowered by research analysts at UBS Group from $158.00 to $135.00 in a research note issued on Monday,MarketScreener reports. The firm presently has a “buy” rating on the healthcare product maker’s stock. UBS Group’s price objective suggests a potential upside of 45.43% from the company’s current price.
A number of other analysts also recently commented on the company. Daiwa Securities Group dropped their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Stifel Nicolaus dropped their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Argus lowered their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Citigroup lowered their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.35.
Read Our Latest Analysis on Abbott Laboratories
Abbott Laboratories Trading Down 3.3%
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.53 EPS for the current year.
Insider Transactions at Abbott Laboratories
In other news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president owned 24,628 shares of the company’s stock, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock worth $353,097 in the last quarter. 0.46% of the stock is owned by corporate insiders.
Institutional Trading of Abbott Laboratories
Several large investors have recently modified their holdings of ABT. J. Stern & Co. LLP grew its stake in shares of Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Norges Bank acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $2,938,892,000. Invesco Ltd. grew its stake in shares of Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Abbott Laboratories by 303.0% during the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock valued at $454,784,000 after acquiring an additional 3,330,368 shares in the last quarter. Finally, Ninety One UK Ltd bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $336,815,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: UBS kept a “buy” rating on ABT, signaling continued conviction in Abbott’s franchise despite trimming its price target — a vote of confidence from a major bank. UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
- Positive Sentiment: Income-minded investors are seeing value: recent coverage highlights a dividend yield near 3% and labels ABT a “dividend king” opportunity for buy-the-dip investors. That supports demand from yield-focused funds. Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity
- Positive Sentiment: Progress on Abbott’s CancerGuard multi-cancer early-detection program and new DETECT A outcomes reinforce the company’s long-term diagnostics growth narrative. Positive clinical/award news can support upside over time. Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story
- Neutral Sentiment: Options-market activity is drawing attention; spikes in put/call flows can foreshadow moves but aren’t a directional confirmation by themselves. Traders may use this as a signal for volatility, not fundamentals. Is the Options Market Predicting a Spike in Abbott Laboratories Stock?
- Neutral Sentiment: Coverage notes that ABT is trading near its 52-week low while many analysts remain bullish — an outlook that supports buy-side interest if sentiment stabilizes. Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love
- Negative Sentiment: Major banks collectively trimmed price targets (multiple firm actions published), creating downward pressure on the stock as headline PT cuts refresh sell-side valuation estimates. This broad re-rating is a primary driver of today’s weakness. Mizuho Cuts Abbott Laboratories Price Target
- Negative Sentiment: UBS and Argus lowered their targets (UBS to $135; Argus to $125) even while keeping buy ratings — a mixed signal that reduces near-term upside expectations vs. prior levels. UBS Adjusts Abbott Laboratories Price Target to $135
- Negative Sentiment: Social and analyst chatter highlights that Q1 results beat estimates but management trimmed full-year guidance (diagnostics headwinds, mild flu season, acquisition costs), which triggered post-earnings selling and still weighs on sentiment. Abbott Laboratories Stock Opinions on Q1 Earnings and Guidance Cut
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Recommended Stories
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
